Genetics Generation Advancement Corp. (TPEX:4160)
Taiwan · Delayed Price · Currency is TWD 43.50
+0.40 (0.93%)
Apr 29, 2026, 1:30 PM CST
TPEX:4160 Revenue
In the year 2025, Genetics Generation Advancement had annual revenue of 603.11M TWD, down -8.88%. Genetics Generation Advancement had revenue of 169.20M in the quarter ending December 31, 2025, with 9.01% growth.
Revenue
603.11M
Revenue Growth
-8.88%
P/S Ratio
1.91
Revenue / Employee
5.80M
Employees
104
Market Cap
1.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 603.11M | -58.74M | -8.88% |
| Dec 31, 2024 | 661.86M | 69.36M | 11.71% |
| Dec 31, 2023 | 592.50M | 44.69M | 8.16% |
| Dec 31, 2022 | 547.81M | 28.30M | 5.45% |
| Dec 31, 2021 | 519.51M | 76.38M | 17.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIONET | 1.24B |
| DIVA Laboratories | 884.63M |
| Kim Forest Enterprise | 549.14M |
| Sofiva Genomics | 385.71M |
| Welgene Biotech | 375.94M |
| Pharmigene | 149.25M |
| Puriblood Medical | 117.35M |